Holen Sie sich die Stockscreener-App
366.49
0.93%
3.98
Schlusskurs vom Vortag:
$362.51
Offen:
$364
24-Stunden-Volumen:
27,589
Relative Volume:
0.08
Marktkapitalisierung:
$41.39B
Einnahmen:
$5.76B
Nettoeinkommen (Verlust:
$514.49M
KGV:
81.78
EPS:
4.4813
Netto-Cashflow:
$1.10B
1W Leistung:
+1.84%
1M Leistung:
+17.26%
6M Leistung:
+1.91%
1J Leistung:
+14.58%
1-Tages-Spanne:
$361.14
$366.20
1-Wochen-Bereich:
$343.50
$365.87
52-Wochen-Spanne:
$253.95
$385.22
Beone Medicines Ltd Adr Stock (ONC) Company Profile
Firmenname
Beone Medicines Ltd Adr
Sektor
Branche
Telefon
41-616851900
Adresse
C/O BEONE MEDICINES I GMBH, BASEL
Compare ONC vs VRTX, REGN, ARGX, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ONC
Beone Medicines Ltd Adr
|
365.91 | 39.31B | 5.76B | 514.49M | 1.10B | 4.4813 |
VRTX
Vertex Pharmaceuticals Inc
|
518.15 | 128.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
809.64 | 82.72B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
980.74 | 53.26B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
212.09 | 43.66B | 742.00K | -1.37B | -1.07B | -7.0731 |
Beone Medicines Ltd Adr Stock (ONC) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-27 | Eingeleitet | Wolfe Research | Outperform |
| 2026-03-16 | Herabstufung | Jefferies | Buy → Hold |
| 2025-11-24 | Eingeleitet | Truist | Buy |
| 2025-09-18 | Eingeleitet | Barclays | Overweight |
| 2025-04-07 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2025-03-03 | Hochstufung | BofA Securities | Neutral → Buy |
| 2024-12-03 | Fortgesetzt | Morgan Stanley | Overweight |
| 2024-09-18 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2024-02-06 | Fortgesetzt | JP Morgan | Overweight |
| 2023-09-12 | Eingeleitet | Macquarie | Outperform |
| 2023-08-17 | Eingeleitet | Jefferies | Buy |
| 2023-07-17 | Eingeleitet | Citigroup | Buy |
| 2023-06-30 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2023-01-12 | Eingeleitet | Daiwa Securities | Buy |
| 2022-10-13 | Hochstufung | Guggenheim | Neutral → Buy |
| 2022-10-13 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2022-08-09 | Fortgesetzt | JP Morgan | Overweight |
| 2022-03-17 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2022-02-07 | Eingeleitet | Deutsche Bank | Buy |
| 2021-10-12 | Eingeleitet | Bernstein | Outperform |
| 2021-10-06 | Hochstufung | CLSA | Underperform → Buy |
| 2021-03-08 | Eingeleitet | China Renaissance | Buy |
| 2021-03-01 | Herabstufung | CLSA | Outperform → Underperform |
| 2020-11-09 | Herabstufung | Ladenburg Thalmann | Buy → Neutral |
| 2020-11-06 | Herabstufung | Maxim Group | Buy → Hold |
| 2020-11-06 | Herabstufung | Piper Sandler | Neutral → Underweight |
Alle ansehen
Beone Medicines Ltd Adr Aktie (ONC) Neueste Nachrichten
BeOne Medicines stock rises nearly 4% as buyers control session amid bullish technicals - Traders Union
BeOne Medicines (ONC) Secures Rights To Four RAS(ON) Inhibitors In Asia - Sahm
BeOne Medicines (NASDAQ:ONC) SVP Sells 2,666 Shares of Stock - MarketBeat
Insider Selling: BeOne Medicines (NASDAQ:ONC) CEO Sells $25,661,243.30 in Stock - MarketBeat
BeOne Medicines (NASDAQ:ONC) CEO Sells $19,659,569.80 in Stock - MarketBeat
BeOne Medicines Ltd.Sponsored ADR (NASDAQ:ONC) Given Average Recommendation of "Buy" by Brokerages - MarketBeat
Generali Investments Management Co LLC Buys Shares of 8,000 BeOne Medicines Ltd.Sponsored ADR $ONC - MarketBeat
The Manufacturers Life Insurance Company Trims Stake in BeOne Medicines Ltd.Sponsored ADR $ONC - MarketBeat
Charles Schwab Trust Co Acquires New Position in BeOne Medicines Ltd.Sponsored ADR $ONC - MarketBeat
Dimensional Fund Advisors LP Raises Position in BeOne Medicines Ltd.Sponsored ADR $ONC - MarketBeat
BeOne Medicines shares gain about 5.5% after robust Q2 results and new Phase 3 trials announcement - Traders Union
BeOne Medicines Q2 Earnings Call Highlights - sharewise.com
BeOne Medicines (NASDAQ:ONC) CFO Sells $361,805.47 in Stock - MarketBeat
Countdown to BeOne Medicines Ltd.Sponsored ADR (ONC) Q2 Earnings: A Look at Estimates Beyond Revenue and EPS - Yahoo Finance
Insider Selling: BeOne Medicines (NASDAQ:ONC) SVP Sells 1,044 Shares - MarketBeat
65,456 Shares in BeOne Medicines Ltd.Sponsored ADR $ONC Bought by Renaissance Technologies LLC - MarketBeat
ADAR1 Capital Management LLC Makes New Investment in BeOne Medicines Ltd.Sponsored ADR $ONC - MarketBeat
Insider Selling: BeOne Medicines (NASDAQ:ONC) CEO Sells $15,086,671.00 in Stock - MarketBeat
Rokos Capital Management LLP Purchases Shares of 14,335 BeOne Medicines Ltd.Sponsored ADR $ONC - MarketBeat
BR:B1ME34 Stock Latest News - TipRanks
BeOne Medicines AG (ONC) stock price, news, quote and history - Yahoo Finance Singapore
ONC Stock Quote Price and Forecast - CNN
Siren L.L.C. Has $138.09 Million Stock Position in BeOne Medicines Ltd.Sponsored ADR $ONC - MarketBeat
Temasek Holdings Private Ltd Cuts Stock Position in BeOne Medicines Ltd.Sponsored ADR $ONC - MarketBeat
ABN Amro Investment Solutions Has $14.12 Million Stake in BeOne Medicines Ltd.Sponsored ADR $ONC - MarketBeat
SEB Asset Management AB Invests $16.65 Million in BeOne Medicines Ltd.Sponsored ADR $ONC - MarketBeat
Jennison Associates LLC Purchases 78,027 Shares of BeOne Medicines Ltd.Sponsored ADR $ONC - MarketBeat
Assetmark Inc. Increases Stock Holdings in BeOne Medicines Ltd.Sponsored ADR $ONC - MarketBeat
AIA Group Ltd Acquires 3,430 Shares of BeOne Medicines Ltd.Sponsored ADR $ONC - MarketBeat
BeOne Medicines (NASDAQ:ONC) CEO Sells 145,861 Shares of Stock - MarketBeat
BeOne Medicines (NASDAQ:ONC) CEO John Oyler Sells 11,698 Shares - MarketBeat
BeOne Medicines (NASDAQ:ONC) CEO John Oyler Sells 48,520 Shares of Stock - MarketBeat
Candriam S.C.A. Grows Stake in BeOne Medicines Ltd.Sponsored ADR $ONC - MarketBeat
Insider Selling: BeOne Medicines (NASDAQ:ONC) SVP Sells 664 Shares of Stock - MarketBeat
ETFs Investing in BeOne Medicines Ltd. Sponsored ADR Stocks - TradingView
ONCBeOne Medicines Ltd ADR Options - Finviz
ONC News | BEONE MEDICINES LTD-ADR (NASDAQ:ONC) - ChartMill
BeOne Medicines Advances Chemotherapy-Free Lymphoma Strategy - Sahm
49BA Forecast — Price Target — Prediction for 2027 - TradingView
Price to sales forward of BeOne Medicines Ltd. Sponsored ADR – DUS:49BA - TradingView
A1437N Forecast — Price Target — Prediction for 2027 - TradingView
Enterprise value to revenue forward of BeOne Medicines Ltd. Sponsored ADR – DUS:49BA - TradingView
Price to book forward of BeOne Medicines Ltd. Sponsored ADR – DUS:49BA - TradingView
Enterprise value to revenue forward of BeOne Medicines Ltd. Sponsored ADR – TURQUOISE:ONCN - TradingView
BeOne Medicines Ltd. Sponsored ADR Actuals & Estimates (NASDAQ:ONC) - TradingView
Finanzdaten der Beone Medicines Ltd Adr-Aktie (ONC)
Umsatz
Nettogewinn
Free Cashflow
ENV
Beone Medicines Ltd Adr-Aktie (ONC) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Lee Chan Henry | SVP, General Counsel |
Aug 11 '26 |
Sale |
360.00 |
2,666 |
959,760 |
0 |
| OYLER JOHN | Chief Executive Officer |
Aug 10 '26 |
Sale |
357.87 |
115,011 |
41,159,461 |
125,799 |
| OYLER JOHN | Chief Executive Officer |
Aug 11 '26 |
Sale |
361.90 |
70,907 |
25,661,417 |
54,892 |
| OYLER JOHN | Chief Executive Officer |
Aug 12 '26 |
Sale |
358.15 |
54,892 |
19,659,594 |
0 |
0.06%
1.29%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):